|Bid||13.87 x 1100|
|Ask||14.10 x 3000|
|Day's Range||13.96 - 14.13|
|52 Week Range||13.15 - 21.33|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-26.66%|
|Beta (5Y Monthly)||0.00|
|Expense Ratio (net)||0.75%|
Yahoo Finance's Alexandra Semenova discusses the anticipated new fund from Cathie Wood's Ark Invest that will blend assets in the private and public markets.
Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that on April 20, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nas
George Nield, Commercial Space Technologies, LLC President, sits down with Yahoo Finance Live to discuss the outlook on commercial space travel, the upcoming Blue Origin space flight, and the benefits of private companies investing in the sciences behind space flight.